Regeneron: FDA accepts for Priority Review sBLA for Evkeeza

Regeneron Pharmaceuticals announced the U.S. FDA has accepted for Priority Review the supplemental Biologics License Application for Evkeeza as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia. The FDA target action date is March 30, 2023.